3
Announcements
Trials
Browse
Landscape
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Thyroid Nodule
2
Pain
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Agnosia
2
Prostatic Neoplasms
1
Neuroma
1
Neuralgia
1
Neoplasm Metastasis
1
Myoma
1
Multiple Pulmonary Nodules
1
Multiple Advanced Tumors After PD-1 Therapy Failure
1
Menorrhagia
1
Lymphoma, Follicular
1
Lipoma
1
Leiomyoma
1
Hypesthesia
1
Hyperthyroidism
1
Hyperaldosteronism
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Cicatrix
1
Carcinoma, Renal Cell
1
Breast Cancer Female
1
Bone Cancer Metastatic
1
Barrett Esophagus
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
ACTH Syndrome, Ectopic
1
Interventions
Oxaliplatin
19
pembrolizumab
13
Fluorouracil
12
Leucovorin
11
Capecitabine
11
Paclitaxel
10
Gemcitabine
8
Docetaxel
8
zolbetuximab
6
cemiplimab
6
Cisplatin
6
Albumin-Bound Paclitaxel
6
durvalumab
5
Ramucirumab
5
Radiotherapy
5
Irinotecan
4
Cyclophosphamide
4
130-nm albumin-bound paclitaxel
4
trastuzumab deruxtecan
3
tislelizumab
3
lenvatinib
3
enzalutamide
3
darolutamide
3
Trastuzumab
3
Taxes
3
S 1 (combination)
3
Radiosurgery
3
Pemetrexed
3
Nivolumab
3
Carboplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
Radiofrequency Ablation
×
1 year
×
Clear all
NCT07237399
2026-05-13
TA-P-OLIM
University Hospital, Ghent
Withdrawn